Libmeldy (Atidarsagene Autotemcel)

Atidarsagene autotemcel, the active ingredient in Libmeldy, is a gene therapy (autologous hematopoietic stem cell transduction) presented as an ex vivo gene‑modified autologous CD34+ cell suspension for intravenous use. It treats metachromatic leukodystrophy in eligible patients.

GNH USA supplies Libmeldy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Libmeldy is used as a one‑time gene‑therapy intervention for the lysosomal storage disorder metachromatic leukodystrophy.

Metachromatic leukodystrophy: provides a single infusion of autologous, gene‑corrected stem cells intended to restore arylsulfatase A activity and slow disease progression.

Libmeldy may be associated with a range of adverse events following the infusion of gene‑modified cells.

Common Side Effects: - Infusion‑related reactions: fever, chills, or flushing during or shortly after administration. - Transient cytopenias: temporary reductions in blood cell counts such as neutropenia or thrombocytopenia. - Gastrointestinal symptoms: nausea, vomiting, or abdominal discomfort. - Fatigue or malaise: general feeling of tiredness in the days after infusion.

Serious or Rare Side Effects: - Insertional mutagenesis: potential for vector integration to cause malignant transformation. - Graft failure or poor engraftment: insufficient stem‑cell engraftment leading to inadequate enzyme production. - Severe infections: opportunistic infections due to immune suppression during conditioning. - Autoimmune reactions: development of antibodies against the introduced enzyme or vector components.

Prior to administering Libmeldy, several precautions should be observed to ensure patient safety and product integrity. - Patient eligibility: confirm diagnosis of metachromatic leukodystrophy and assess disease stage per approved criteria. - Pre‑infusion conditioning: use appropriate chemotherapy regimen to facilitate stem‑cell engraftment. - Monitoring: conduct regular hematologic and neurological assessments after infusion. - Infection control: implement prophylactic antimicrobial measures during immunosuppression. - Pregnancy and lactation: avoid use in pregnant or breastfeeding individuals unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Libmeldy can interact with other therapies, primarily those affecting immune function or stem‑cell biology.

Major Interactions (Avoid): - Live attenuated vaccines: administration may lead to uncontrolled infection. - Concurrent chemotherapy agents not part of the conditioning protocol: may impair engraftment. - Strong immunosuppressants beyond the prescribed regimen: increase risk of severe infections.

Moderate Interactions (Monitor Closely): - Antiviral prophylaxis (e.g., acyclovir): monitor renal function and adjust dosing if needed. - Growth factor support (e.g., G‑CSF): may influence stem‑cell proliferation; observe blood counts. - Immunoglobulin replacement therapy: assess for potential interference with immune reconstitution.